Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

NCT03464916 ·Status: COMPLETED ·Phase: PHASE1

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584 ·Status: RECRUITING

Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma

NCT02394210 ·Status: TERMINATED

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

NCT06523621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

NCT05361694 ·Status: RECRUITING

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

NCT00036140 ·Status: COMPLETED ·Phase: PHASE1

Precision Medicine Study

NCT06338150 ·Status: RECRUITING

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

NCT05908396 ·Status: TERMINATED ·Phase: PHASE1

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318 ·Status: RECRUITING

Multiple Myeloma Patient Registry

NCT03180853 ·Status: TERMINATED

Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

NCT03836014 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

NCT04035226 ·Status: COMPLETED

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

NCT05372354 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

NCT06183489 ·Status: RECRUITING ·Phase: PHASE2

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

NCT06212323 ·Status: RECRUITING

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

NCT00405756 ·Status: COMPLETED ·Phase: PHASE3

Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients

NCT01160107 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+

NCT06874530 ·Status: RECRUITING

PRospective Multiple Myeloma Impact Study

NCT02911571 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03361748 ·Status: COMPLETED ·Phase: PHASE2

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841 ·Status: RECRUITING ·Phase: PHASE3

Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM

NCT06205823 ·Status: ACTIVE_NOT_RECRUITING

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

NCT02181413 ·Status: COMPLETED ·Phase: PHASE3

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

NCT02561962 ·Status: COMPLETED ·Phase: PHASE1